News

Filter

Current filters:

fidaxomicinDificid

Optimer Pharma could earn $90 million from new Astellas deal

30-03-2012

US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

US FDA advisory panel backs Optimer novel antibiotic Dificid for CDI

07-04-2011

The US Food and Drug Administration's Anti-Infective Drugs Advisory Committee has recommended that the…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidfidaxomicinNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulation

COMPANY SPOTLIGHT

Menarini

Back to top